Nassim Usman, new Totus Medicines CEO

To­tus Med­i­cines clos­es $66M Se­ries B to fund ear­ly-stage PI3Ka in­hibitor, names new CEO

Small mol­e­cule biotech To­tus Med­i­cines has closed a $66 mil­lion Se­ries B to car­ry its PI3Kα in­hibitor through Phase Ia and has named Nas­sim Us­man as its new pres­i­dent and CEO.

The Emeryville, CA-based To­tus, which emerged with a $40 mil­lion Se­ries A in De­cem­ber 2021, closed the Se­ries B in re­cent weeks af­ter Us­man joined, he told End­points News. He re­places found­ing CEO Neil Dhawan, who will re­main as chief sci­en­tif­ic of­fi­cer and add on head of R&D re­spon­si­bil­i­ties, To­tus said Fri­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.